Contact SCGE




Clinical Trial Report

Gene Therapy Trial Report

Summary

PDE6A Gene Therapy for Retinitis Pigmentosa


NCTID NCT04611503 (View at clinicaltrials.gov)
Description
Development Status Active
Indication Retinitis Pigmentosa
Disease Ontology Term DOID:0110379
Compound Name RAAV.hPDE6A
Sponsor STZ eyetrial
Funder Type Other
Recruitment Status
Active not recruiting
Enrollment Count 9
Results Posted Not Available

Therapy Information


Target Gene/Variant PDE6A
Therapy Type Gene transfer
Therapy Route In-vivo
Mechanism of Action Functional gene replacement
Route of Administration Subretinal
Drug Product Type Viral vector
Target Tissue/Cell
Delivery System Viral transduction
Vector Type AAV8
Editor Type none
Dose 1 1E9 vg
Dose 2 5E9 vg
Dose 3 1E10 vg
Dose 4 5E10 vg
Dose 5

Study Record Dates


Current Stage Phase1, Phase2
Submit Date 2020-05-20
Completion Date 2027-07
Last Update 2024-04-18

Participation Criteria


Eligible Age >=18 Years
Standard Ages Adult, Older adult
Sexes Eligible for Study ALL

Locations


No.of Trial Sites 1
Locations Germany

Regulatory Information


Has US IND False
FDA Designations
Recent Updates

Resources/Links